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Abstract 
 
Aim: Postpartum anemia is a common problem in obstetrics. Depending on the 
severity of anemia, it can cause a wide range of symptoms. Obstetrical management 
should be focused on avoiding blood transfusion in young and otherwise healthy 
women. Aim of this study was to examine the effectiveness of rhEPO combined with 
iron sucrose compared to iron sucrose alone in patients with severe postpartum 
anemia. 
Methods: Prospective randomized study in women with severe postpartum anemia 
(Hb < 8.5 g/dL). Group one received 200mg iron sucrose intravenously daily on days 
1-4. The second group received 200mg iron sucrose plus 10.000E rhEPO in the 
same regimen. 20 women were enrolled in each group. Follow-up was two weeks. 
Results: Baseline Hb was 7.1 g/dL and 7.5 g/dL respectively depending on the 
subgroup. Hemoglobin values increased close to normal values within two weeks in 
both groups treated with iron sucrose alone or in combination with rhEPO (10.5 g/dL, 
10.7 g/dL, respectively).  
Conclusions: In general, iron sucrose alone is a sufficient anemia therapy agent.  A 
subgroup of patients (i.e. with a more pronounced inflammatory response after 
caesarean section) may benefit from additional rhEPO therapy. Despite being 
severely anemic, none of our patients required transfusion. Iron sucrose as well as 
rhEPO was very well tolerated. The benefit of the therapy lies in the avoidance of 
allogenic blood transfusions with their potential side effects. In cases of severe 
anemia after operative delivery additional rhEPO therapy can result in a faster Hb 
increase and therefore faster recovery. 
Key words: anemia, iron-deficiency, iron-sucrose, postpartum, recombinant EPO 
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Introduction 
 
Postpartum anemia is a common problem in obstetrics. Depending on the grade 
of anemia, symptoms like reduced exercise performance, tiredness, headache, 
increased cardiovascular strain, higher risk for infections, and lactation 
problems occur. As in other specialties, anemia often results in a longer stay in 
hospital.1 According to WHO criteria severe anemia is defined by a hemoglobin 
value < 8.5 g/dL. 2,3 
The known risks of allogenic blood transfusions for treatment of severe anemia, 
as transmission of pathogens (i.e. Hepatitis B/C, HIV, and CMV), 
alloimmunization and immunosuppression, led to the search for alternative 
therapeutic options. 4,5 
Several studies in have shown the superiority of IV iron over oral iron in the 
treatment of postpartum anemia. IV iron not only corrects anemia faster, but is 
also second to none in replenishing iron stores.6-8 
Recombinant human erythropoietin (rhEPO) is successfully used since the mid 
1980‘s for treatment of renal anemia. RhEPO is not only well established in the 
treatment of anemia under chemotherapy, anemia of chronic disease, 
perioperative correction of anemia or autologous blood donation 9-11 but as well 
in the correction of anemia in pregnancy and postpartum. 12-15 
Elevation of inflammation mediators in chronic or inflammatory disease 
interferes with iron utilization.16 With the discovery of hepcidin as a key regulator 
of iron absorption and distribution a major step has been made in the 
understanding of iron metabolism and pathogenesis of anemia of 
inflammation.17 Studies showed a connection between elevated cytokine levels 
(TNF alpha, IL1) and inadequate erythropoietin response.18 Similar to the 
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changes observed in anemia of chronic disease, even minor surgical 
procedures as well as vaginal delivery already lead to a rise in cytokine levels, 
which are possibly responsible for suppressed erythropoiesis. 19,20 Different 
studies showed the effectiveness of rhEPO in insufficient erythropoiesis due to 
inadequate endogenous erythropoietin levels.21,22 Admittedly, Wagstrom et al.  
showed that iv iron alone might be sufficient in treating severe postpartum 
anemia.15 
The main handicap of rhEPO therapy is its high cost. Therefore, aim of this 
study was to examine the effectiveness of IV iron sucrose with and without the 
combination of rhEPO in the treatment of postpartum anemia and if there are, to 
define patients who profit from additional rhEPO therapy. In contrast to previous 
studies 22-24 we selected only patients with severe postpartum anemia (Hb < 8.5 
g/dL). As in earlier studies, we opted to use an amount of iron (800 mg) which 
should be sufficient to treat the grade of anemia and to restore iron stores 
sufficiently. Furthermore, as we tried to establish a therapy scheme ready for 
routine use, our aim was to simplify this scheme as much as possible. The 
same holds true for the chosen rhEPO dosage. 10.000 U rhEPO daily reflects a 
mean dosage of 150 U / kg bodyweight, which is a commonly used medium 
rhEPO dose.  
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Material and Methods 
 
In this prospective, randomized single-center study 40 postpartum women 
with severe anemia (Hb < 8.5 g/dL) were included. 
The inclusion criteria were prepartal hemoglobin > 10.0 g/dL, severe 
postpartum anemia, defined by a hemoglobin < 8.5 g/dL 24 – 48 h after 
delivery. Exclusion criteria were any hematological, chronic-inflammatory 
or malignant disease, cardiac or renal dysfunction, hemosiderosis, history 
of iron intolerance, peripartal blood transfusion. 
Patients were randomized using sealed envelops containing numbers 
allocated to one of two gr ups. 
All women gave informed consent and the study was approved by the 
hospital ethics committee which is a division of the cantonal ethics 
committee in Zurich. 
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Treatment 
 
Treatment was started between 24 and 48 hours after delivery and 
administered daily on 4 subsequent days. 
Group I (n=20)): iron sucrose (Venofer, Vifor, St.Gallen, Switzerland), 
200 mg (=10 mL) via intravenous (i.v.) catheter daily on days 1-4 (no 
rhEPO placebo was used); 
Group II (n=20): rhEPO (Eprex, Janssen-Cilag, Baar, Switzerland) 
(10.000 U daily) via i.v. catheter on days 1-4 plus iron sucrose (identical as 
in group I). 
All treatments were administered at room temperature. The iron sucrose 
complex was administered first and was diluted in 250 mL 0.9 % sodium 
chloride, followed by 5 mL saline to flush iron particles from the tubing. 
Where applicable, rhEPO followed as a bolus, again followed by 5 mL 
saline.  
The study was conducted over a 24 moths period between 2004 and 
2006. 
 
Laboratory investigations 
 
Blood samples were taken before, and 4, 7 and 14 days after start of 
therapy. On day 4, blood samples were taken before administering 
medication intravenously. 
Hematocrit, hemoglobin, red cell indices (mean corpuscular volume, MCV; 
mean corpuscular hemoglobin, MCH; mean corpuscular hemoglobin 
concentration, MCHC), percentage of hypochromic red cells, and 
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reticulocyte count were determined using Advia analyzer (Bayer 
Diagnostics, Leverkusen, Germany). 
Measures of iron status were serum ferritin, obtained by 
immunochemiluminescence (Elecsys Systems, Roche AG, Switzerland), 
transferrin saturation and soluble transferrin receptor concentration, 
measured by enzyme immunoassay based upon the double antibody 
sandwich method (Ramco Laboratories, Houston, Texas, USA). C-reactive 
protein (CRP) was determined by immunoprecipitation, folic acid 
concentration in erythrocytes, and vitamin B12 and erythropoietin levels by 
radioimmunoassay. Interleukin 6 was measured using 
chemiluminescence- enzyme immunoassay.  
 
Statistical analysis  
 
Groups were compared using the Mann-Whitney test.  
Based on the hemoglobin increase on day 15, post-hoc power calculation 
revealed a power of 0.87. 
A significance level of p < 0.05 was used in all tests. Statistics were 
calculated using Statview software (SAS Institute Inc., Cary, NC, USA).
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Results 
 
Patients characteristics 
 
40 women were included. Mean gestational age at delivery was 38 weeks 
(24–42 weeks). Delivery was spontaneous in 19 of cases, vaginal 
operative in 8, and via caesarean section in 13 cases. Estimated blood 
loss was 838 ± 600 mL (250–2150 mL). Reasons for hemorrhage were: 
retention of placenta (8), placental abruption (5), atonic bleeding (3), 
fibroids (2) and placenta previa (1). The remaining women delivered 
without any further complications apart from anemia. 
 
Baseline data  
 
Mean prepartal hemoglobin was 11.5 ± 1.1 g/dL (range 10.0 – 15.1 g/dL), 
and mean postpartum hemoglobin was 7.3 ± 0.9 g/dL (5.0 – 8.4 g/dL) 
[mean hematocrit 22.2 ± 2.8 %, (16.0 – 26.7%)]. Mean postpartum 
(=baseline) ferritin was 38 ± 55 µg/L (median 24; 2 – 312 µg/L). 
At baseline vitamin B12 and folic acid levels were within the normal range, 
except one patient with a vitamin B12 value of 121 ng/L, which is below 
the lower limit of 180 ng/L. There were no statistically significant 
differences between the two groups in baseline data. 
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Erythropoietic response  
 
In the overall population the mean hemoglobin increase one week after 
start of treatment was 2.1 ± 0.1 g/dL (0.6 – 3.9g/dL) (∆Hct 7.2 ± 0.4 %; 3.4 
– 12.9%), after two weeks 3.3 ± 0.1 g/dL (1.6 – 4.8g/dL) (∆Hct 10.9 ± 0.3 
%; 6.0 – 16.1%). Absolute hemoglobin values one and two weeks after 
start of therapy were 9.4 ± 0.2 g/dL (7.0  – 11.9g/dL) and 10.6 ± 0.1 g/dL 
(8.6  – 12.6g/dL), respectively (hematocrit: 29,5 ± 0.6 %; 20.9  – 36.9 after 
one week and 33.1 ± 0.4%; 27.2 – 38.9 after two weeks) (Fig. 1).  
Subgroup values for baseline and end of treatment are shown in table 1.  
From day 4  after start of treatment the difference between the hemoglobin 
increase was statistically significant between group I (iron sucrose alone) 
and group II (iron sucrose + rhEPO)  (day 4: 0.5 (± 0.1) g/dL vs. 1.0 (± 0.2) 
g/dL; p < 0.05; day 8: 1.9 (± 0.1) g/dL vs. 2.4 (± 0.2) g/dL; p < 0.05; day 
15: 3.0 (± 0.1) g/dL vs. 3.9 (± 0.1) g/dL; p < 0.05). 
Reticulocytes showed an increase from baseline in both groups until day 8 
and returned to values comparable to baseline data on day 15. 
Reticulocytosis was statistically significantly higher in the group treated 
with iron and rhEPO (Fig. 2a). 
Endogenous EPO (eEPO) levels at baseline were elevated in all patients 
with no statistically significant difference in both groups (mean 154 U/L ± 
21, range 33 – 589 U/L). After the end of treatment endogenous EPO 
levels decreased continuously to day 15 with no statistically significant 
difference in both groups (overall mean 29 U/L, ± 2, range 8 – 69 U/L). 
There was no correlation between the grade of anemia and eEPO prior to 
therapy (Hb p = 0.07, r2 = 0.087; Hct p = 0.12, r2 = 0.065).  
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Iron status  
 
Baseline and end of study data are shown in table 1. Highest ferritin levels 
were measured on day 4 [mean 453 µg/L, median 443 (211 – 863 µg/L)], 
decreasing continuously to day 15 [mean 206 µg/L, median 187 (88 – 461 
µg/L)]. There was no statistically significant difference between both 
groups throughout the study period.  
Hypochromic erythrocytes increased in both groups during the study 
period. Percentage of hypochromic erythrocytes was statistically 
significantly higher in the rhEPO group than in the group treated with iron 
alone on days 8 and 15 (Fig. 2b). 
Soluble transferrin receptor (sTfR) levels were elevated in both groups at 
baseline and increased further throughout the study period. On day 8 sTfR 
levels in the rhEPO group were statistically significantly higher than in the 
iron alone treated group (Fig. 2c).  
 
Inflammatory reaction 
 
CRP levels were elevated at baseline in all patients (mean 57 ± 6 mg/L) 
but almost normalized by day 15 (mean 6 ± 1 mg/L). There was no 
statistically significant difference between both groups.  
Baseline Interleukin 6 (IL-6) levels were elevated in all patients (mean 18 ± 
3 ng/L) and almost normalized by the end of the study period (mean 5 ± 
0.3 ng/L) with no statistically significant difference between both groups 
whatsoever.   
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Patient subgroups  
 
To identify patients at greatest potential benefit from additional rhEPO 
therapy we performed a subgroup analysis according to the mode of 
delivery.  
At comparison of women who underwent caesarean section (n = 13), the 
increase in hemoglobin levels was statistically significantly higher in the 
subgroup treated with additional rhEPO (n = 6) compared to women 
receiving IV iron alone (n = 7). Women after caesarean section showed 
statistically significantly lower eEPO levels but statistically significantly 
higher IL-6 levels compared to women who gave birth spontaneously or 
had a vaginal operative delivery (n = 27).  
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Safety 
 
Assessment of vital signs was comparable between the groups throughout 
the study. There were no serious adverse reactions to rhEPO or iron 
sucrose. There was no hypo- or hypertensive response during therapy. No 
thromboembolic complications were seen. Minor side-effects were metallic 
taste in 12 patients, and 3 patients reported warm flush over a few 
minutes. Treatment was well tolerated overall in terms of both clinical and 
patient self-evaluation. No patient needed blood transfusion in addition to 
therapy. 
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Discussion 
 
In conclusion intravenous iron sucrose is effective and safe in treating 
severe anemia in a postpartum population. Additional rhEPO could be 
indicated for patients especially after operative delivery with serious 
anemia related symptoms or refusing transfusions in which case rhEPO 
represents the most effective therapy alternative. 
In this study we were able to show a marked increase of hemoglobin and 
hematocrit values close to normal within two weeks in both groups treated 
with iron sucrose alone or in combination with rhEPO. Despite being 
severely anemic, none of our patients required transfusion. The benefit of 
the therapy clearly lies in the avoidance of allogenic blood transfusions 
with their potential side effects, such as infection or alloimmunization.4 
Depending on the severity of anemia, patients suffer from increased 
cardiovascular strain, autonomous dysregulation, reduced exercise 
performance and various symptoms such as tiredness and dizziness. 
Furthermore it negatively affects the course of the puerperium, the ability 
to breastfeed and duration of hospitalization.23,25 
Already one week after start of treatment, patients in group II had a 
statistically significant higher increase in hemoglobin levels than patients 
treated with iron alone (group I). This is in contrast to the study of 
Wagstrom et al who examined a similar protocol in women with a 
comparable grade of postpartum anemia.15 The main differences to our 
study are a lower total iron dose, a lower rhEPO dose, or a longer interval 
between rhEPO applications respectively.  We agree with Wagstrom and 
colleagues that intravenous iron alone is sufficient in treating severe 
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postpartum anemia but identified a subgroup which profits from additional 
rhEPO therapy. Our data obtained from patients after cesarean section 
show statistically significant higher IL-6 levels and statistically significant 
lower eEPO levels, whereas baseline hemoglobin levels are the same 
compared to patients after vaginal delivery. After delivery inflammatory 
mediators are released, which are causing suppressed erythropoiesis and 
alteration of iron metabolism in postpartum anemia.19 20 Cytokine release 
leads to increased iron absorption in macrophages and the reticulo-
endothelial system.20 It is suggested, that these cytokine triggered 
processes also influence anemia of chronic, rheumatoid or inflammatory 
disease.26 In the postoperative situation inflammatory mediators seem to 
be increased in comparison to spontaneous delivery.  
We believe, in patients after operative delivery combined therapy with iron 
sucrose and rhEPO is beneficial. 
In our study there was no correlation between the grade of anemia and 
eEPO levels as suggested by Cazzola et al.21 This circumstance might be 
explained by cytokine activation as described above. 
Additional rhEPO therapy leads to a statistically significant increase of 
reticulocytes by day 8 in the rhEPO treated group, but despite IV iron 
supplementation aggravates functional iron deficiency shown by a higher 
percentage of hypochromic red cells and higher sTfR levels (Fig. 2a-c). 
However, together with postpartum reduction of maternal total red cell 
mass, decline of pregnancy-induced hydremia, reduced iron loss due to 
postpartum amenorrhea, the substituted amount of iron should be 
sufficient not only to correct anemia but also to restore body iron stores.  
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Intravenous iron administration is safe, especially if iron sucrose is used. 
Hoigné et al. published adverse event profiles of 4 different databases 
(8100 patients) and calculated a adverse event rate of 0.36% with not a 
single life threatening event.27 RhEPO therapy is usually well tolerated as 
well, adverse events, such as hypertension are described mainly in 
patients with chronic renal failure.28  As millions of anemic patients with a 
variety of indications have been treated with different epoetin preparations, 
some years ago cases of epoetin-associated pure red cell aplasia (PRCA) 
have been identified and raised questions on safety of the drug.29 As these 
cases occurred in hemodialysis patients who received epoetins 
subcutaneously for several months we believe PRCA is not an issue in the 
short-term treatment setting, particularly if rhEPO is given intravenously. 
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Figure Legends 
Figure 1. Erythropoietic response. Increase of hemoglobin versus day 0 in 
patients receiving iron sucrose alone (red line) or iron sucrose plus rhEPO (blue 
line). Asterisk, P < .05. 
Figure 2. Reticulocyte count (a), Hypochromic red blood cell count (b), soluble 
transferrin receptor concentration (c) in patients receiving iron sucrose alone 
(red line) or iron sucrose plus rhEPO (blue line).  Asterisk, P < .05. 
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Table 1: Baseline and end of treatment data for groups I and II (Data are given 
as mean ± SD)  
  
Group I 
(iv iron) 
n=20 
Group II 
(iv iron 
+rhEPO) 
n=20 
p 
Baseline 7.5±0.7 7.1±1.1 ns Hemoglobin 
(g/dL) End of Treatment 10.5±0.7 10.7±1.2 ns 
Baseline 22.8±2.2 21.4±3.3 ns 
Hematocrit (%) 
End of Treatment 32.9±1.9 33.4±3.5 ns 
Baseline 3.0±0.8 3.8±1.8 ns Reticulocytes 
(%) End of Treatment 3.7±1.3 3.9±1.6 ns 
Baseline 128+74 184±173 ns Endogenous 
EPO (U/L) End of Treatment 29±15 30±16 ns 
Baseline 32±37 46±73 ns 
Ferritin (µg/L) 
End of Treatment 221±102 187±89 ns 
Baseline 5±3 6±8 ns Soluble 
Transferrin-
receptor (µg/ml) End of Treatment 11±3 12±3 ns 
Baseline 56±36 57±38 ns C-reactive 
protein (mg/L) End of Treatment 8±7 4±3 ns 
Baseline 21±26 14±12 ns Interleukin 6 
(ng/L) End of Treatment 5±1 5±2 ns 
Vit. B12 (ng/L) Baseline 298±142 257±86 ns 
Blood loss (mL) Baseline 817±579 864±643 ns 
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